The historical rank and industry rank for Royalty Pharma's FCF Margin % or its related term are showing as below:
RPRX'
s FCF Margin % Range Over the Past 10 Years
Min: 88.12 Med: 91.9 Max: 126.89
Current: 126.89
During the past 7 years, the highest FCF Margin % of Royalty Pharma was 126.89%. The lowest was 88.12%. And the median was 91.90%.
RPRX's FCF Margin % is ranked better than 98.35% of 1032
companies
in the Biotechnology industry
Industry Median: -148.935
vs RPRX: 126.89
Royalty Pharma FCF Margin % Historical Data
The historical data trend for Royalty Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Royalty Pharma's FCF Margin %
For the Biotechnology subindustry, Royalty Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's FCF Margin % falls into.
Royalty Pharma FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Royalty Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma FCF Margin % Related Terms
Thank you for viewing the detailed overview of Royalty Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Royalty Pharma (Royalty Pharma) Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPRX has been successfully added to your 